source
- Radioligand therapy gains momentum as experts discuss expanding patient impactIn a recent episode of the Denatured podcast presented by Curium, host Jennifer Smith-Parker spoke with Mike Patterson, CEO North America, and Sabine Brookman-May, Vice President and Head of Global…
- Henlius Biotech signs $440 million deal with Amberstone to develop T-cell engagersHenlius Biotech, a subsidiary of Fosun Pharma, announced a licensing agreement with California‑based Amberstone Biosciences valued at up to $440 million. The partnership will focus on creating anti…